NK-081

N/A

Report date: 2024/11/12 15:24:13

Base Information

Drug NameNK-081
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III modulators
TargetsLow affinity immunoglobulin gamma Fc region receptor III
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai NK CellTech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai NK CellTech Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A